Hi everyone, Looking for advice on the MDX2003 trial vs. self-funding CAR-T in Israel for Mantle Cell Lymphoma...
Understanding Your Situation
Your partner has had two lines of therapy with a relatively short remission (6 months) after the second line. This pattern suggests aggressive disease that may benefit from more intensive approaches like CAR-T therapy or novel treatments.
What We Know About CAR-T for MCL
CAR-T therapy has shown strong results in relapsed/refractory MCL:
- According to NCCN Guidelines, CAR-T (specifically brexucabtagene autoleucel/Tecartus) is an established option for relapsed MCL after 2+ prior therapies
- Response rates in clinical trials have been impressive, with many patients achieving complete remission
- The challenge is access, which you've identified
Key considerations for international CAR-T:
- Manufacturing time: CAR-T requires collecting your partner's T-cells, shipping them for modification, and waiting 3-4 weeks for manufacturing
- Post-treatment monitoring: Patients need to stay near the treatment center for 4-6 weeks minimum to monitor for serious side effects (cytokine release syndrome, neurotoxicity)
- Bridging therapy: You may need treatment while waiting for CAR-T manufacturing to control disease progression
About the MDX2003 Trial
Based on the webinar content available, I don't have specific information about the MDX2003 trial design or results. However, I can share general principles about evaluating clinical trials:
Questions to ask your trial team:
- What is the mechanism of action of MDX2003? (Is it an antibody, small molecule, bispecific, etc.?)
- What phase is the trial? (Phase 1 focuses on safety; Phase 2/3 on efficacy)
- What response rates have been seen in MCL patients specifically?
- What are the expected side effects and monitoring requirements?
- If this trial doesn't work, would CAR-T still be an option afterward?
- How does the trial timeline compare to accessing CAR-T?
Practical Considerations for Israel CAR-T
Logistical factors to investigate:
- Total cost: Manufacturing, hospital stay, monitoring, accommodations (typically $300,000-500,000+ USD for international patients)
- Travel restrictions: Can your partner travel safely given current disease status?
- Support system: Who can accompany your partner for the extended stay?
- Follow-up care: How will long-term monitoring work once you return to Australia?
- Insurance/financial: Some international patients have successfully negotiated with insurers or used medical tourism facilitators
From the webinar context, accessing treatments internationally is possible but requires careful planning. One webinar participant mentioned: "There's a lot of discussion about the Mayo or Moffitt centers and other centers of excellence and just how I might pursue treatment options given that I'm still at the initial start of what could be quite an accelerated period."
Alternative Approaches to Consider
1. Telemedicine consultation with CAR-T centers: According to webinar discussions, some major cancer centers (MD Anderson, Memorial Sloan Kettering, City of Hope) offer telemedicine consultations and may have trial options or compassionate use programs.
2. Bispecific antibodies: The webinars mention that bispecific T-cell engagers are showing strong results in blood cancers and may be more accessible than CAR-T. According to Cancer Commons expert Emma Shtivelman: "Bispecifics are now [available] because they're obviously easier to use, because they work really well in DLBCL, and the results in follicular lymphoma and so on. So it's a good option."
Questions to ask your oncologist:
- Are there any bispecific antibody trials available in Australia for MCL?
- Would bispecific therapy be an option if MDX2003 doesn't work?
- What is the expected timeline for disease progression without treatment?
- If we pursue Israel CAR-T, what bridging therapy would you recommend during manufacturing?
- Are there compassionate use programs for approved CAR-T products in Australia?
Decision Framework
Consider MDX2003 trial if:
- It's a Phase 2/3 trial with promising early data
- The mechanism targets a vulnerability in your partner's specific MCL
- It preserves CAR-T as a future option
- Your partner's disease is stable enough to try this first
Consider Israel CAR-T if:
- Disease is progressing rapidly and needs definitive treatment
- You have financial resources and support system in place
- Your partner is medically fit for travel and intensive therapy
- The trial has significant unknowns or is very early phase
Resources for Further Research
For clinical trial information:
- ClinicalTrials.gov (search "mantle cell lymphoma" + "Australia" or specific trial number)
- Leukemia & Lymphoma Society has trial matching services
- Cancer Commons offers treatment navigation services
For CAR-T access:
- Contact Israeli hospitals directly (Sheba Medical Center, Hadassah Medical Center are known for treating international patients)
- Consider medical tourism facilitators who specialize in oncology
- Explore whether your Australian private insurance has international coverage provisions
Critical Next Steps
- Get detailed MDX2003 trial information - mechanism, phase, preliminary results
- Request second opinion from an MCL specialist (even via telemedicine)
- Assess disease tempo - how quickly is it progressing? This affects timing urgency
- Investigate all CAR-T access routes - trials, compassionate use, international options
- Consider bridging therapy - what can control disease while you make this decision?
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Your situation highlights the real challenges patients face with geographic treatment access. I'd encourage you to also reach out to MCL-specific patient advocacy groups (Lymphoma Australia, Lymphoma Coalition) who may have experience helping patients navigate international treatment access.
What specific aspects of this decision would be most helpful to explore further?
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated November 3, 2026. Informational only — not a substitute for your oncology team.
Question asked:
Hi everyone, Looking for advice on the MDX2003 trial vs. self-funding CAR-T in Israel for Mantle Cell Lymphoma (MCL). We are in a tough spot in Australia. We don't have Medicare to access standard CAR-T here, and there are no local trials open to us. My partner was diagnosed with MCL in July 2025. Here is the treatment history: • Line 1: Bendamustine + Rituximab (6 months) – partial response. • Line 2: Zanubrutinib + Sonrotoclax trial – reached remission, but relapsed after 6 months. Our team has offered the MDX2003 trial, but we are also strongly considering going to Israel for CAR-T. Does anyone have experience with the MDX2003 trial, or any advice on traveling to Israel for CAR-T as an international patient? Thank you so much.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with treatment for Mantle cell lymphoma patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Mantle cell lymphoma
- Good evening everyone, I'm writing from Italy. I recently received a diagnosis of mantle cell lymphoma. Is anyone...
- Has anyone ever done a water fast for their mantle cell lymphoma? How long and with what results? Thank you in...
- Hi everyone, I’m looking for recommendations on apps or calendars that can help track treatment cycles and...
- Extreme leg cramps. I have non Hodgkin mantle cell lymphoma stage 4. I have extreme cramps usually in my calves or...
- My father did IHC test. The report says CD5-positive B-cell Non-Hodgkin's Lymphoma, likely Mantle Cell Lymphoma or...
- Is CAR-T cell therapy available for PIK3CA-Mutant Breast Cancer
- Hi, is there anyone in treatment for Meitl lymphoma
- Looking for advice from my fellow NET warriors. I had surgery/ablations for my small-bowel NET liver mets in July...